The Psychotherapist’s Essential Guide To The Brain

Part 14 – Depression Part 2

Matthew Dahlitz

Members Download Article: TNPTVol5Issue3pp8-17

[Content protected for subscribers only]

Not A Subscriber?

If you are a subscriber and do not see the download button you may not be logged in

Last month we covered multiple brain areas implicated in depression. Readers will have appreciated the complexity of the changes depression can entail in the neural network. This month we endeavor to throw light on the role of neurochemicals, genetics, and neuroplasticity, in order to arrive at a more accurate and holistic understanding of how depression affects the individual.

Neurochemicals in Depression

Evidence has mounted since the 1950s that serotonergic systems play a major role in depression. Central to this understanding early on was the observation that raising the level of serotonin appeared to reduce the symptoms of depression. The “monoamine hypothesis” of depression suggests that a deficiency in monoamines, including serotonin, causes the symptoms of depression. Prima facie, this logic appears reasonable, but does not necessarily explain causality.

Early experimental evidence supported the serotonin depletion hypothesis. For example, there were found to be fewer serotonin transporter sites on platelets in depressed patients (Healy & Leonard, 1987), and less metabolic product (5-HTAA, from the breakdown of serotonin) was observed in cerebrospinal fluid (Cheetham, Katona, & Horton, 1991). But just to complicate matters, other studies have found no evidence of reduced serotonergic function in depressed patients (Gjerris, 1988). However, the monoamine hypothesis received support in the form of observations that the drug reserpine, which depletes monoamines, seemed to increase depressive symptoms. Armed with this knowledge, researchers looked at how to selectively increase synaptic serotonin levels, which led to the creation of selective serotonin reuptake inhibitors (SSRIs).

During the 1970s and 1980s there was also a focus on monoamine receptors, and how receptor density and sensitivity changed in response to different therapies, especially antidepressants. Generally the body of research supported the hypothesis that depression is marked by impaired serotonergic and adrenergic activity, with effective drug therapy increasing one or both of these systems (Palazidou, 2012). We know that presynaptic serotonergic cells have autoreceptors that monitor the amount of serotonin released by the cell. These receptors regulate the amount of serotonin release in tandem with the reuptake transporters that take serotonin from the synaptic cleft and back into the presynaptic cell. Antidepressants, by blocking reuptake mechanisms and forcing more monoamines to stay in the synaptic cleft, increase the serotonergic activity of cells in a matter of days, and autoreceptors quickly adapt to the increase in serotonin. The firing rate of the monoaminergic neurons is initially decreased to compensate for the increase in circulating monoamines, but the inhibition diminishes over time, and a therapeutic effect is felt by the patient (Lambert & Kinsley, 2005).

Another theory linking neurochemicals and depression rests on the catecholamine hypothesis introduced by Joseph Schildkraut in 1965. This theory postulates that depression is a result of norepinephrine (NE) deficiency, and that an overabundance of NE leads to manic states. Although SSRIs had already produced clinically significant results in dealing with depression, the notion of a relationship between depleted NE and depression was supported by research (Delgado & Moreno, 2000; Nemeroff, 1998). It is noteworthy that, as in the case of serotonin, NE depletion does not induce clinical depression in healthy people—the cause of depression appears to be more complex than simple imbalances in these levels. It is likely that depression may be a result of dysfunction in brain areas modulated by monoamine systems. The same probably holds for the involvement of another monoamine, dopamine, which has also been implicated in depression and the manifestation of anhedonia (the inability to feel pleasure in normally pleasurable activities; Treadway & Zald, 2011).

Genetics in Depression

The early dominance of the monoamine hypothesis, which postulates that depressive symptoms are the result of decreased serotonin, noradrenalin, and possibly dopamine, has given way to alternative theories that consider neural dysfunction and genetic factors. In fact, a meta-analysis of major depression in twins concluded that the disorder is a familial one, albeit complex, arising from the combined effect of genetic and environmental influences (Sullivan, Neale, & Kendler, 2000). Epigenetic studies have been investigating how individual environmental factors modulate gene expression in depression. For instance, the 3A serotonin genotype (HTR3A-42C>T) is associated with gray-matter loss in the hippocampus and PFC in depressed individuals who have experienced early-life stress (Gatt et al., 2010). And just as we saw with the rhesus monkeys, human carriers of the 5-HTTLPR short allele are more prone to depression if they have suffered one or more earlier stressful life events, giving more support to the idea that an individual’s response to environmental stress is moderated by genetic makeup (Caspi et al., 2003; Karg, Burmeister, Shedden, & Sen, 2011).

Get your copy from Amazon

Another line of research implicates brain-derived neurotropic factor (BDNF), which is involved in the growth of new neurons in the hippocampus and represents an important mechanism of adult brain plasticity. Stress suppresses BDNF synthesis in the hippocampus, and depressed patients have been shown to have lower serum BDNF concentrations than healthy subjects. Antidepressants and electroconvulsive therapy seem to increase BDNF serum concentrations and reduce depressive symptoms (Piccinni et al., 2009; Shimizu et al., 2003). BDNF seems a good candidate for study in depression, as BDNF genetic variations influence brain areas related to mood (Palazidou, 2012). The Met allele BDNF genotype has been associated with abnormal secretion of BDNF, abnormal hippocampal neuronal function, and impaired episodic memory (Hariri et al., 2003) as well as smaller hippocampal volume (Frodl, Möller, & Meisenzahl, 2008). However, the evidence for the involvement of BDNF in the pathophysiology of depression is inconsistent and does not support a simple causal relationship between total brain BDNF levels and mood (Groves, 2007). Rather, the role of BDNF in modulating activity-dependent plasticity within emotional processing networks may be compromised in depression. In other words, BDNF may not control mood directly, but is critical in the process that determines how a plastic change influences mood (Castrén, Võikar, & Rantamäki, 2007)…

 

This has been an excerpt from The Neuropsychotherapist’s Essential Guide to the Brain Part 14 – Depression Part 2. To download the full article, and more excellent material for the psychotherapist, please subscribe to our monthly magazine.

References

Andrade, C., & Rao, N. S. K. (2010). How antidepressant drugs act: A primer on neuroplasticity as the eventual mediator of antidepressant efficacy. Indian Journal of Psychiatry, 52, 378–386. doi:10.4103/0019-5545.74318

Andrews, P. W., Bharwani, A., Lee, L. R., Fox, M., & Thomson, J. A., Jr. (2015). Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response. Neuroscience & Biobehavioral Reviews, 51, 164–188. doi:10.1016/j.neubiorev.2015.01.018

Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., . . . Poulton, R. (2003). Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science, 301(5631), 386–389. doi:10.1126/science.1083968

Castrén, E., & Hen, R. (2013). Neuronal plasticity and antidepressant actions. Trends in Neurosciences, 36, 259–267. doi:10.1016/j.tins.2012.12.010

Castrén, E., Võikar, V., & Rantamäki, T. (2007). Role of neurotrophic factors in depression. Current Opinion in Pharmacology, 7, 18–21. doi:10.1016/j.coph.2006.08.009

Cheetham, S. C., Katona, C. L. E., & Horton, R. W. (1991). Post-mortem studies of neurotransmitter biochemistry in depression and suicide. In R. W. Horton & C. L. E. Katona (Eds.), Biological aspects of affective disorders (pp. 192–221). London, United Kingdom: Academic Press.

Dinan, T. G., & Cryan, J. F. (2013). Melancholic microbes: A link between gut microbiota and depression? Neurogastroenterology & Motility, 25, 713–719. doi:10.1111/nmo.12198

Duman, R. S., & Aghajanian, G. K. (2012). Synaptic dysfunction in depression: Potential therapeutic targets. Science, 338(6103), 68–72. doi:10.1126/science.1222939

Duman, R. S., & Voleti, B. (2012). Signaling pathways underlying the pathophysiology and treatment of depression: Novel mechanisms for rapid-acting agents. Trends in Neurosciences, 35, 47–56. doi:10.1016/j.tins.2011.11.004

Eisch, A. J., & Petrik, D. (2012). Depression and hippocampal neurogenesis: A road to remission? Science, 338(6103), 72–75. doi:10.1126/science.1222941

Evrensel, A., & Ceylan, M. E. (2015). The gut–brain axis: The missing link in depression. Clinical Psychopharmacology and Neuroscience, 13, 239–244. doi:10.9758/cpn.2015.13.3.239

Frodl, T., Möller, H.-J., & Meisenzahl, E. (2008). Neuroimaging genetics: New perspectives in research on major depression? Acta Psychiatrica Scandinavica, 118, 363–372. doi:10.1111/j.1600-0447.2008.01225.x

Gatt, J. M., Williams, L. M., Schofield, P. R., Dobson-Stone, C., Paul, R. H., Grieve, S. M., . . . Nemeroff, C. B. (2010). Impact of the HTR3A gene with early life trauma on emotional brain networks and depressed mood. Depression and Anxiety, 27, 752–759. doi:10.1002/da.20726

Gjerris, A. (1988). Baseline studies on transmitter substances in cerebrospinal fluid in depression. Acta Psychiatrica Scandinavica, 78, 1–35. doi:10.1111/j.1600-0447.1988.tb10571.x

Groves, J. O. (2007). Is it time to reassess the BDNF hypothesis of depression? Molecular Psychiatry, 12, 1079–1088. doi:10.1038/sj.mp.4002075

Hariri, A. R., Goldberg, T. E., Mattay, V. S., Kolachana, B. S., Callicott, J. H., Egan, M. F., & Weinberger, D. R. (2003). Brain-derived neurotrophic factor Val66Met polymorphism affects human memory-related hippocampal activity and predicts memory performance. Journal of Neuroscience, 23, 6690–6694.

Healy, D., & Leonard, B. E. (1987). Monoamine transport in depression: Kinetics and dynamics. Journal of Affective Disorders, 12, 91–103.

Holtzheimer, P. E., Kelley, M. E., Gross, R. E., Filkowski, M. M., Garlow, S. J., Barrocas, A., . . . Mayberg, H. S. (2012). Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Archives of General Psychiatry, 69, 150–158. doi:10.1001/archgenpsychiatry.2011.1456

Karg, K., Burmeister, M., Shedden, K., & Sen, S. (2011). The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: Evidence of genetic moderation. Archives of General Psychiatry, 68, 444–454. doi:10.1001/archgenpsychiatry.2010.189

Lozano, A. M., Giacobbe, P., Hamani, C., Rizvi, S. J., Kennedy, S. H., Kolivakis, T. T., . . . Mayberg, H. S. (2012). A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. Journal of Neurosurgery, 116, 315–322. doi:10.3171/2011.10.JNS102122

Lozano, A. M., Mayberg, H. S., Giacobbe, P., Hamani, C., Craddock, R. C., & Kennedy, S. H. (2008). Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biological Psychiatry, 64, 461–467. doi:10.1016/j.biopsych.2008.05.034

Nemeroff, C. B. (1998). The neurobiology of depression. Scientific American, 278, 42–49. doi:10.1038/scientificamerican0698-42

Piccinni, A., Del Debbio, A., Medda, P., Bianchi, C., Roncaglia, I., Veltri, A., . . . Dell’Osso, L. (2009). Plasma brain-derived neurotrophic factor in treatment-resistant depressed patients receiving electroconvulsive therapy. European Neuropsychopharmacology, 19, 349–355. doi:10.1016/j.euroneuro.2009.01.002

Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders: A review of supporting evidence. American Journal of Psychiatry, 122, 509–522.

Shelton, R. C., & Miller, A. H. (2010). Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depression. Progress in Neurobiology, 91, 275–299. doi:10.1016/j.pneurobio.2010.04.004

Shimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., . . . Iyo, M. (2003). Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biological Psychiatry, 54, 70–75.

Sukoff Rizzo, S. J., Neal, S. J., Hughes, Z. A., Beyna, M., Rosenzweig-Lipson, S., Moss, S. J., & Brandon, N. J. (2012). Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Translational Psychiatry, 2, e199. doi:10.1038/tp.2012.120

Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000). Genetic epidemiology of major depression: Review and meta-analysis. The American Journal of Psychiatry, 157, 1552–1562. doi10.1176/appi.ajp.157.10.1552

Suomi, S. J. (1999). Attachment in rhesus monkeys. In J. Cassidy & P. R. Shaver (Eds.), Handbook of attachment: Theory, research, and clinical applications (pp. 181–197). New York, NY: Guilford Press.

Treadway, M. T., & Zald, D. H. (2011). Reconsidering anhedonia in depression: Lessons from translational neuroscience. Neuroscience & Biobehavioral Reviews, 35, 537–555. doi:10.1016/j.neubiorev.2010.06.006

Villanueva, R. (2013). Neurobiology of major depressive disorder. Neural Plasticity, 2013, e873278. doi:10.1155/2013/873278

Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nature Reviews Neuroscience, 11, 642–651. doi:10.1038/nrn2884